Sol-Gel Technologies Ltd
SLGL
Company Profile
Business description
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
Contact
7 Golda Meir Street
Weizmann Science Park
Ness Ziona7403650
ISRT: +972 89313433
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
28
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Proposed legislation removes health insurance rebates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,717.00 | 82.40 | -0.94% |
| CAC 40 | 8,117.42 | 135.66 | 1.70% |
| DAX 40 | 24,737.24 | 336.59 | 1.38% |
| Dow JONES (US) | 49,871.12 | 507.24 | 1.03% |
| FTSE 100 | 10,432.34 | 101.79 | 0.99% |
| HKSE | 25,651.12 | 146.73 | -0.57% |
| NASDAQ | 26,168.30 | 297.59 | 1.15% |
| Nikkei 225 | 59,804.41 | 746.18 | -1.23% |
| NZX 50 Index | 12,761.03 | 213.29 | -1.64% |
| S&P 500 | 7,412.64 | 59.03 | 0.80% |
| S&P/ASX 200 | 8,496.60 | 76.50 | -0.89% |
| SSE Composite Index | 4,162.18 | 7.35 | -0.18% |